Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;51(2):183-92.
doi: 10.1007/s12016-016-8544-9.

A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE)

Konrad Bork  1
Affiliations
Review

A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE)

Konrad Bork. Clin Rev Allergy Immunol. 2016 Oct.

Abstract

Hereditary angioedema (HAE) due to C1 esterase inhibitor (C1-INH) deficiency (HAE-C1-INH) is a rare but medically significant disease that can be associated with considerable morbidity and mortality. Research into the pathogenesis of HAE-C1-INH has expanded greatly in the last six decades and has led to new clinical trials with novel therapeutic agents and treatment strategies. Mechanisms of pharmacotherapy include (a) supplementing C1-INH, the missing serine-protease inhibitor in HAE; (b) inhibiting the activation of the contact system and the uncontrolled release of proteases in the kallikrein-kinin system, by blocking the production/function of its components; (c) inhibiting the fibrinolytic system by blocking the production/function of its components; and (d) inhibiting the function of bradykinin at the endothelial level. Strategies for managing HAE-C1-INH are aimed at treating acute attacks, or preventing attacks, through the use of prophylactic treatment. Available agents for treating acute attacks include plasma-derived C1-INH concentrates, a recombinant C1-INH, a bradykinin B2 receptor antagonist, and a plasma kallikrein inhibitor. Long-term prophylactic treatments include attenuated androgens, plasma-derived C1-INH concentrates, and anti-fibrinolytics. Plasma-derived C1-INH and a bradykinin B2 receptor antagonist are already approved for self-administration at home. The number of management options for HAE-C1-INH has increased considerably within the past decade, thus helping to alleviate the burden of this rare disease.

Keywords: C1 inhibitor; C1-INH deficiency; Hereditary angioedema; Prophylaxis; Treatment for acute attacks.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eur J Clin Invest. 2011 Mar;41(3):256-62 - PubMed
    1. J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):77-84 - PubMed
    1. J Allergy Clin Immunol. 2009 Oct;124(4):801-8 - PubMed
    1. Pediatrics. 2013 Aug;132(2):e490-7 - PubMed
    1. Ann Allergy Asthma Immunol. 2014 Feb;112(2):163-169.e1 - PubMed

MeSH terms

LinkOut - more resources